Cometta A, Gallot-Lavallée-Villars S, Iten A, Cantoni L, Anderegg A, Gonvers J J, Glauser M P
Division des Maladies Infectieuses, CHUV, Lausanne, Switzerland.
J Antimicrob Chemother. 1990 Apr;25(4):689-95. doi: 10.1093/jac/25.4.689.
Ceftriaxone has potent activity against a broad range of Gram-positive and Gram-negative bacteria. While it is eliminated mainly by the kidney, 10-20% of the drug is eliminated in the bile and ceftriaxone salt precipitates have been described in the gallbladder of animals dosed with ceftriaxone. The purpose of the present study was to investigate the incidence of biliary lithiasis 6 and 12 months after treatment with ceftriaxone and to compare it with that in patients treated with amoxycillin/clavulanate. Biliary ultrasonography was performed at the start of treatment, at 6 months and at 12 months after the beginning of the study. One hundred patients were randomized and 74 were evaluable: 34 were given amoxycillin/clavulanate, 40 ceftriaxone. Gallbladder lithiasis developed in one patient 12 months after the amoxycillin/clavulanate treatment and in none in the ceftriaxone treatment arm. Biliary precipitate during ceftriaxone treatment was not looked for because this phenomenon was not known at the beginning of the study, but gallbladder precipitation that was seen in two patients given ceftriaxone during and at the end of treatment, respectively, resolved spontaneously. In conclusion, ceftriaxone treatment does not appear to lead to gallstone formation more often than an antibiotic that is not eliminated through the bile.
头孢曲松对多种革兰氏阳性菌和革兰氏阴性菌具有强大的活性。虽然它主要通过肾脏排泄,但10%-20%的药物通过胆汁排泄,并且在接受头孢曲松给药的动物胆囊中已发现头孢曲松盐沉淀。本研究的目的是调查头孢曲松治疗6个月和12个月后胆石症的发生率,并将其与接受阿莫西林/克拉维酸治疗的患者进行比较。在治疗开始时、研究开始后6个月和12个月进行了胆道超声检查。100名患者被随机分组,74名可评估:34名给予阿莫西林/克拉维酸,40名给予头孢曲松。阿莫西林/克拉维酸治疗12个月后有1例患者发生胆囊结石,而头孢曲松治疗组无病例发生。由于在研究开始时不知道这种现象,因此未对头孢曲松治疗期间的胆汁沉淀进行研究,但分别在两名接受头孢曲松治疗的患者治疗期间和治疗结束时观察到的胆囊沉淀均自发消退。总之,与一种不通过胆汁排泄的抗生素相比,头孢曲松治疗似乎不会更频繁地导致胆结石形成。